Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: flickerful who wrote (276)	12/15/1997 9:19:00 AM
From: 5,17,37,5,101,...	Read Replies (1) \| Respond to of 756

Randy, Apparently shortsellers and some big institutions figured BM-S had the trump card and availed themselves of that fateful Ivx Sept rally. Too bad Ivx didn't announce this to shareholders. That said, I still believe Paxene has a slim chance if the FDA determines that it is indeed different from Paclitaxel. I think that if Paxene produces fewer side effects and/or is more effective than Paclitaxel, then Paclitaxel's orphan status is negated. Isn't this what Ivax is claiming in their application? This is what we should find out from the FDA when they make their announcement. Does the FDA announce public rejection of a drug application? Thanks for the candlestick shtik. Jackson